AustralieFrV1, Main, Curation, bibRecord, 006D20

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Identifieur interne : 006D20 ( Main/Curation ); précédent : 006D19; suivant : 006D21

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Auteurs : H. Ascher-Svanum [États-Unis] ; X. Peng [États-Unis] ; W. Montgomery [Australie] ; D. E. Faries [États-Unis] ; A. H. Lawson [États-Unis] ; M. M. Witte [États-Unis] ; D. Novick [Royaume-Uni] ; N. Jemiai [Royaume-Uni] ; E. Perrin [France] ; D. P. Mcdonnell [Royaume-Uni]

Source :

European psychiatry [ 0924-9338 ] ; 2011.

RBID : Pascal:11-0339142

Descripteurs français

Pascal (Inist)
- Evaluation, Voie orale, Neuroleptique, Olanzapine, Forme libération contrôlée, Traitement, Schizophrénie, Psychotrope, Antipsychotique atypique, Forme pharmaceutique.

English descriptors

KwdEn :
- Atypical antipsychotic, Controlled release form, Dosage form, Evaluation, Neuroleptic, Olanzapine, Oral administration, Psychotropic, Schizophrenia, Treatment.

Abstract

Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A83
to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002206
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :004461
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001D31
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007182

Links to Exploration step

Pascal:11-0339142

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia</title>
<author><name sortKey="Ascher Svanum, H" sort="Ascher Svanum, H" uniqKey="Ascher Svanum H" first="H." last="Ascher-Svanum">H. Ascher-Svanum</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peng, X" sort="Peng, X" uniqKey="Peng X" first="X." last="Peng">X. Peng</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montgomery, W" sort="Montgomery, W" uniqKey="Montgomery W" first="W." last="Montgomery">W. Montgomery</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Eli Lilly Australia Pty Ltd, 112, Wharf Road</s1>
<s2>West Ryde NSW 2114</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>West Ryde NSW 2114</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faries, D E" sort="Faries, D E" uniqKey="Faries D" first="D. E." last="Faries">D. E. Faries</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lawson, A H" sort="Lawson, A H" uniqKey="Lawson A" first="A. H." last="Lawson">A. H. Lawson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Witte, M M" sort="Witte, M M" uniqKey="Witte M" first="M. M." last="Witte">M. M. Witte</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Lilly USA, LLC, Lilly Corporate Center, DC 4133</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Novick, D" sort="Novick, D" uniqKey="Novick D" first="D." last="Novick">D. Novick</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Surrey, GU20 6PH</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jemiai, N" sort="Jemiai, N" uniqKey="Jemiai N" first="N." last="Jemiai">N. Jemiai</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Surrey, GU20 6PH</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Perrin, E" sort="Perrin, E" uniqKey="Perrin E" first="E." last="Perrin">E. Perrin</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Eli Lilly and Company Limited, 13, rue Pagès</s1>
<s2>92158 Suresnes</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92158 Suresnes</wicri:noRegion>
<wicri:noRegion>rue Pagès</wicri:noRegion>
<wicri:noRegion>92158 Suresnes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, D P" sort="Mcdonnell, D P" uniqKey="Mcdonnell D" first="D. P." last="Mcdonnell">D. P. Mcdonnell</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Eli Lilly and Company Limited, Cork ELCL</s1>
<s2>DC 6158</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>DC 6158</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0339142</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0339142 INIST</idno>
<idno type="RBID">Pascal:11-0339142</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A83</idno>
<idno type="stanalyst">FRANCIS 11-0339142 INIST</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002206</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004461</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D31</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001D31</idno>
<idno type="wicri:doubleKey">0924-9338:2011:Ascher Svanum H:assessing:the:infrequent</idno>
<idno type="wicri:Area/Main/Merge">007182</idno>
<idno type="wicri:Area/Main/Curation">006D20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia</title>
<author><name sortKey="Ascher Svanum, H" sort="Ascher Svanum, H" uniqKey="Ascher Svanum H" first="H." last="Ascher-Svanum">H. Ascher-Svanum</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peng, X" sort="Peng, X" uniqKey="Peng X" first="X." last="Peng">X. Peng</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montgomery, W" sort="Montgomery, W" uniqKey="Montgomery W" first="W." last="Montgomery">W. Montgomery</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Eli Lilly Australia Pty Ltd, 112, Wharf Road</s1>
<s2>West Ryde NSW 2114</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>West Ryde NSW 2114</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Faries, D E" sort="Faries, D E" uniqKey="Faries D" first="D. E." last="Faries">D. E. Faries</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Eli Lilly and Company, Lilly Corporate Center, Drop Code 5024</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lawson, A H" sort="Lawson, A H" uniqKey="Lawson A" first="A. H." last="Lawson">A. H. Lawson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Lilly Corporate Center, DC 4133, Eli Lilly and Company</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Witte, M M" sort="Witte, M M" uniqKey="Witte M" first="M. M." last="Witte">M. M. Witte</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Lilly USA, LLC, Lilly Corporate Center, DC 4133</s1>
<s2>Indianapolis, IN 46285</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Indianapolis, IN 46285</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Novick, D" sort="Novick, D" uniqKey="Novick D" first="D." last="Novick">D. Novick</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Surrey, GU20 6PH</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jemiai, N" sort="Jemiai, N" uniqKey="Jemiai N" first="N." last="Jemiai">N. Jemiai</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham</s1>
<s2>Surrey, GU20 6PH</s2>
<s3>GBR</s3>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Surrey, GU20 6PH</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Perrin, E" sort="Perrin, E" uniqKey="Perrin E" first="E." last="Perrin">E. Perrin</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Eli Lilly and Company Limited, 13, rue Pagès</s1>
<s2>92158 Suresnes</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>92158 Suresnes</wicri:noRegion>
<wicri:noRegion>rue Pagès</wicri:noRegion>
<wicri:noRegion>92158 Suresnes</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcdonnell, D P" sort="Mcdonnell, D P" uniqKey="Mcdonnell D" first="D. P." last="Mcdonnell">D. P. Mcdonnell</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Eli Lilly and Company Limited, Cork ELCL</s1>
<s2>DC 6158</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>DC 6158</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European psychiatry</title>
<title level="j" type="abbreviated">Eur. psychiatr.</title>
<idno type="ISSN">0924-9338</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European psychiatry</title>
<title level="j" type="abbreviated">Eur. psychiatr.</title>
<idno type="ISSN">0924-9338</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atypical antipsychotic</term>
<term>Controlled release form</term>
<term>Dosage form</term>
<term>Evaluation</term>
<term>Neuroleptic</term>
<term>Olanzapine</term>
<term>Oral administration</term>
<term>Psychotropic</term>
<term>Schizophrenia</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Evaluation</term>
<term>Voie orale</term>
<term>Neuroleptique</term>
<term>Olanzapine</term>
<term>Forme libération contrôlée</term>
<term>Traitement</term>
<term>Schizophrénie</term>
<term>Psychotrope</term>
<term>Antipsychotique atypique</term>
<term>Forme pharmaceutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: Adding another antipsychotic to a treatment regimen was previously used in evaluating the medication's efficacy. Supplementation of depot antipsychotics with oral antipsychotics is particularly meaningful because depot formulations are typically chosen for patients struggling with adherence to oral antipsychotics. This post-hoc analysis assessed supplementation of olanzapine long-acting injection (olanzapine-LAI) with oral olanzapine. Subjects and methods: We used 12 months of data from an open-label, single-arm extension study of patients with schizophrenia or schizoaffective disorder (N = 931) treated with olanzapine-LAI. The prevalence, duration, time to first supplementation, and best predictors of oral supplementation were assessed. Results: Oral supplementation occurred in 2 1 % of patients for a median of 31 days with mean modal dose of 10.8 mg/day. Mean time to first supplementation was shorter for patients who were at least moderately ill at baseline compared to less ill patients (47 vs. 97 days, p < 0.001 Best predictors of oral supplementation included a more severe illness profile at baseline, lower olanzapine-LAI dose prior to oral supplementation, supervised living arrangements, and being African-American. Conclusion: Supplementation of olanzapine-LAI appears to be infrequent, of relatively short duration, and reserved for more severely ill patients who may require a targeted rescue medication due to signs of impending relapse.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006D20 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 006D20 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:11-0339142
   |texte=   Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri